Xeno Biosciences Inc., a company focused on advancing therapies for obesity and metabolic diseases, has initiated a Phase 1b clinical study to evaluate the efficacy, safety, and tolerability of its drug candidate XEN-101 in obese adults. This study aims to demonstrate proof-of-concept for weight loss using an optimized formulation of XEN-101. The trial, conducted in Australia, employs a double-blinded, randomized, placebo-controlled, parallel-group design involving multiple doses of XEN-101 administered over a 4-week period to 32 adults with BMI between 30 and 45 kg/m².
Primary objectives include assessing safety, tolerability, and total body weight change at the 4-week endpoint. Secondary endpoints encompass pharmacodynamic effects such as microbiome composition, serum ketone levels, metabolic biomarkers, and changes in self-reported appetite and hunger.
Dr. Dennis Kim, President and CEO of Xeno Biosciences, expressed confidence in the study’s ability to deliver promising weight reduction results within the established safety profile of XEN-101. “With its daily oral administration and innovative mechanism of action, XEN-101 has the potential to address significant unmet needs in the obesity treatment landscape,” Dr. Kim noted. The company anticipates disclosing top-line results from the Phase 1b study by the conclusion of 2024.
About Xeno Biosciences Inc.
Xeno Biosciences Inc. is dedicated to developing safe and effective therapies for obesity and metabolic diseases. Its lead candidate, XEN-101, aims to provide a well-tolerated, orally administered alternative to existing treatments, leveraging insights from Roux-en-Y Gastric Bypass Surgery. Initial clinical trials have demonstrated XEN-101’s strong safety profile and tolerability.
This press release contains forward-looking statements regarding the company’s financial position, operational results, market positioning, product development, and business strategy. These statements are subject to inherent risks and uncertainties, and actual outcomes may differ materially from expectations. The company assumes no obligation to update forward-looking statements in this release due to new information, future events, or other reasons, except as required by law.
